Abstract: The present invention is produced as a polymerized peptide prepared by oxidatively cross-linking collagen-like peptides having the triple-helical structure containing three peptide chains each containing multiple cysteine (Cys) residues. This polymerized peptide can be processed into a hydrogel and a thin membrane sheet before use, and is capable of imparting a particular physiological function such as cellular adhesion by incorporating functional amino acid sequences present on biological polymers. Further, the present invention provides a method for producing the abovementioned polymerized peptide and the like; and use applications employing the same, such as cell culturing, wound dressing, and compositions including regenerative medical materials and research materials.

Abstract: Disclosed here are peptides derived from a serpin reactive center loop that have anti¬inflammatory, anti-atherogenic and anti-sepsis activity. Compositions containing such serpin-derived peptides are therefore useful in the treatment of transplant vascular disease and also for the treatment of hemorrhagic viral infections as well as lethal viral, fungal or bacterial sepsis in patients.

Abstract: The present invention relates to a method for producing a population of 20 or more nucleic acids, each encoding at least one protein comprising at least one immunoglobulin variable domain having a rabbit-derived CDR3 amino acid sequence embedded in essentially human framework sequences, as well as to a population of nucleic acids and a population of proteins relates thereto and uses thereof.

Abstract: Methods to create chemically-induced dimerizing (CID) protein systems and uses thereof are described. The methods utilize antibody binding domain dimerizing proteins. The created systems can be used to regulate cellular events such as gene expression, receptor signaling and cell death to effectuate a variety of clinically relevant treatment outcomes.

Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.

Abstract: Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing Clostridium difficile infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.

Abstract: Anti-CaENO1 antibodies and humanized antibodies are provided as an effective diagnostic agent or a therapeutic treatment against infections caused by Candida spp., preferably Candida albicans, Candida tropicalis, fluconazole resistance Candida spp., Strepcococcus, Staphylococcus.

Abstract: Compositions and methods of use are provided for intrabodies that bind and alter the effects of poly-glutamate protein aggregation in poly-glutamate associated diseases, such as in Huntington's disease. Intrabodies are provided that prevent poly-glutamate aggregation, gene dysregulation, and negative effects of Huntington's disease.

Abstract: The present invention relates to anti-Nodal antibodies and use of the anti-Nodal antibodies for diagnosing, preventing, and treating a Nodal-related disorder or disease.

Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.

Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.

Abstract: Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesive proteins on endothelial cells facilitates metastasis. The role of tumor secreted angiopoietin-like 4 (cANG-PTL4) in vascular leakiness and metastasis is controversial due to the lack of understanding of how cANGPTL4 modulates vascular integrity. Here, we show that cANGPTL4 instigated the disruption of endothelial continuity by directly interacting with three novel binding partners, integrin ?5?1, VE-cadherin and claudin-5, in a temporally sequential manner, thus facilitating metastasis. We showed that cANGPTL4 binds and activates integrin ?5?1-mediated Rac1/PAK signaling to weaken cell-cell contacts. cANGPTL4 subsequently associated with and declustered VE-cadherin and claudin-5, leading to endothelial disruption. Interfacing with the formation of the cANGPTL4 complexes delayed vascular disruption.

Abstract: Provided are an anti-canine TARC antibody for use in the treatment and diagnosis of canine atopic dermatitis, and a method for treating or diagnosing canine atopic dermatitis using the same. An anti-canine TARC monoclonal antibody binding to canine TARC, comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 4, or a functional fragment thereof binding to canine TARC.

Abstract: IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.

Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating asthma, such as severe asthma, by employing IL-17 antagonists to a patient population defined by serum concentration of IgE and optionally also an eosinophil count in peripheral blood.

Abstract: The present invention relates to plexin D1 for use as a targetable protein in the treatment or diagnosis of disorders that involve expression of plexin D1. Diagnosis is suitably effected by detecting the presence of plexin D1 in the body or a bodily tissue or fluid, whereas treatment is effected by targeting plexin D1 for delivery of therapeutics to the site where treatment is needed. The invention further relates to the use of molecules that bind plexin D1, a nucleic acid encoding plexin D1 or a ligand of plexin D1 for the preparation of a therapeutical composition for the treatment or diagnosis of disorders that involve expression of plexin D1. The disorders comprise disorders in which plexin D1 is expressed on tumor cells, tumor blood vessels or activated macrophages.

Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell. Antibodies that are bispecific for SIRP? and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti-SIRP? antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP? antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRP? antibodies.

Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Abstract: Described herein are novel anti-CD3 antibodies conjugated to folate and uses thereof treatment of diseases or conditions that would benefit from such conjugate are provided.

Abstract: Methods of treating a PD-1-resistant cancer are provided and comprise administering to a subject in need thereof a therapeutically effective amount of a c-Rel inhibitor and a therapeutically effective amount of a PD-1 inhibitor. A pharmaceutical combination comprising a therapeutically effective amount of a c-Rel inhibitor, and a therapeutically effective amount of a PD-1 inhibitor is also provided. Finally, methods of treating a cancer such as a CTLA-4-resistant cancer, a CD137-resistant cancer, and an OX-4-resistant cancer are provided and comprise administering to a subject in need thereof a therapeutically effective amount of a c-Rel inhibitor and a therapeutically effective amount of a CLTA-4, CD137 or OX-4 inhibitor, respectively.

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.

Abstract: The present invention relates to a method and a medicament for airway and/or lung diseases such as moderate and/or severe asthma disease, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and systemic sclerosis. The medicament contains an agent which inhibits TL1A-DR3 interaction, and the method involves administering an effective amount of the agent to a subject to inhibit at least one symptom, feature or condition selected from hyperplasia of epithelial cells, epithelial metaplasia, hypertrophy of smooth muscle cells, and hyperproliferation of smooth muscle cells, production of extracellular matrix, and/or airway and/or lung tissue remodeling.

Abstract: Methods and compositions are provided for reversibly localizing proteins to the exterior part of the cell surface. Compositions provided herein can include nucleic acids that encode polypeptides of interest and the ligand binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.

Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.

Abstract: This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, an anti-VEGF antibody, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.

Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.

Abstract: This document provides materials and methods for treating pancreatitis (e.g., severe acute pancreatitis), a complication associated with pancreatitis (e.g., organ failure), and/or an acute inflammatory condition in a mammal (e.g., inflammation from a burn or trauma). For example, methods and materials for using one or more colipase inhibitors to treat a mammal having pancreatitis (e.g., acute pancreatitis) are provided.

Abstract: The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury disease.

Abstract: There are many reports of diseases caused by overeating, satiation, and an unbalanced diet, and various therapeutic methods and therapeutic drugs are proposed for said diseases. There have not been many proposals, for prevention of these diseases, of methods by which what is eaten is not readily absorbed in vivo. The present invention involves inoculating female birds with a digestive enzyme as an antigen, said digestive enzyme being present in vivo. As a result of inhibiting the activity of the digestive enzyme by using an antibody which has been produced in vivo in the birds, the present invention inhibits decomposition of proteins, lipids, and carbohydrates and reduces in vivo absorption. This type of antibody can be obtained from an egg laid by a female bird which has received the antigen, and furthermore the egg itself includes the antibody. Consequently, a food product that contains, as an ingredient thereof, eggs having this type of antibody is low in proteins, lipids, and carbohydrates.

Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.

Abstract: Esterified cellulose ethers which comprise (i) aliphatic monovalent acyl groups or (ii) groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, or (iii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, which have a viscosity of up 19 mPa·s, measured as a 10 wt % solution of the esterified cellulose ether in acetone at 20° C. and which have a weight average molecular weight Mw of at least 90,000 Dalton, are useful for preparing solid dispersions comprising drugs.

Abstract: The invention relates to temporary cross-linked cellulose ethers, a process to make them, as well as their use to influence the rheological profile of an aqueous medium in which they are dissolved. The temporary cross-linked cellulose ethers are characterized in that they are cellulose ethers that are Cross-linked with at least one or more compounds of the formula (C1-4 alkyl)-OC(O)CHOHO—(C1-4 alkyl).

Abstract: The invention relates to a starch hydrolysate having a Dextrose Equivalent DE of between 5 and 30 and a specific carbohydrate profile. In particular, the hydrolysate of the invention has improved retrogradation behaviour. The invention also relates to a method for the production of said starch hydrolysate.

Abstract: The present invention relates to new aqueous curable binder compositions comprising a carbohydrate compound, a first cross linker and a second cross linker different from the first capable of undergoing radical polymerization and possibly a free radical initiator.

Abstract: A method of reducing the amount propylene chlorohydrin produced in a reaction to make a hydroxypropylated/crosslinked starch comprising removing residual propylene oxide from alkaline slurry. The residual propylene oxide is removed by the dewatering the alkaline slurry or by washing the starch in slurry at a pH of around 10. The starch is then neutralized in an acid solution and recovered from the second slurry and may or may not be washed, depending on whether the slurry while at pH around 10 to make a hydroxypropylated/crosslinked starch having less than 1 ppm propylene chlorohydrin.

Abstract: The invention relates to a novel methylated cyclodextrin and to a novel method used for the production thereof. The invention also relates to the use of said methylated cyclodextrin for the solubilisation of lipophilic compounds, or carriers of at least one lipophilic group. The invention further relates to a composition comprising said methylated cyclodextrin, particularly a pharmaceutical composition.

Abstract: The present invention relates to a method for obtaining rubber from rubber-containing plant material, the method comprising the steps of subjecting a composition comprising rubber-containing plant material and a fermentation culture to conditions allowing anaerobic fermentation, wherein the composition preferably has a water content of less than 95 wt. %. The fermentation preferably does not involve movement of the rubber-containing plant material (or parts thereof), and preferably the fermentation is performed in the absence of oxygen ventilation. Additionally, it is preferred that the fermentation culture is cycled through the composition by percolation. A further step of the method involves obtaining the rubber from the composition.

Abstract: A method for preparing a functionalized polymer, the method comprising the steps of preparing a reactive polymer and reacting the reactive polymer with a heterocyclic nitrile compound.

Abstract: The invention relates to an apparatus for producing pulverulent poly(meth)acrylate, comprising a reactor for droplet polymerization having an apparatus for dropletization of a monomer solution for the preparation of the poly(meth)acrylate having holes through which the monomer solution is introduced, an addition point for a gas above the apparatus for dropletization, at least one gas withdrawal point on the circumference of the reactor, a fluidized bed and an apparatus for product discharge from the fluidized bed. The apparatus for product discharge comprises a discharge apparatus, with a backup segment (39) disposed above the discharge apparatus.

Abstract: The present disclosure provides the use of quinolinyldiamido transition metal complexes, an activator and a metal hydrocarbenyl chain transfer agent, such as an aluminum vinyl-transfer agent, to produce long chain branched propylene polymers.

Abstract: Described herein is a polymer comprising: interpolymerized units of (i) a fluorinated terminal alkene monomer and (ii) a tertiary amine-containing fluorinated monomer comprising at least one of a vinyl amine, a substituted vinyl amine, an allyl amine, a substituted allyl amine, and combinations thereof; wherein the polymer can be amorphous or semi-crystalline with a melting point no greater than 325C. Dispersions thereof and methods of making and using the same are also described.

Abstract: A process is described for introducing a catalyst into a polymerization zone by detecting one or a combination of (i) a change in a concentration of the catalyst in a catalyst feed stream upstream of the polymerization zone, (ii) a change in a concentration of monomer in the polymerization zone, and (iii) a change in a polymer production rate of the polymerization zone, adjusting a first catalyst flow rate of the catalyst in the catalyst feed stream to a second catalyst flow rate based on the one or a combination of (i), (ii), and (iii), and introducing the catalyst into the polymerization zone downstream of a location in the catalyst feed stream where the step of adjusting is performed. A catalyst injection system for carrying out such a process is also provided.

Abstract: The invention provides a composition comprising a first ethylene-based polymer, formed by a high pressure, free-radical polymerization process, and comprising the following properties: a) a Mw(abs) versus I2 relationship: Mw(abs)<A×[(I2)B], where A=5.00×102 (g/mole)/(dg/min)B, and B=?0.40; and b) a MS versus I2 relationship: MS?C×[(I2)D], where C=13.5 cN/(dg/min)D, and D=?0.55.

Abstract: The invention relates to a thickened preparation comprising a polymer which can be obtained by radical emulsion polymerization of at least one acidic vinyl monomer or salt thereof, at least one non-ionic vinyl monomer, in particular preferably a hydrophobic non-ionic vinyl monomer, at least one monomer containing an unsaturated terminal group and a polyoxyalkyene portion, at least one crosslinking monomer, optionally a protective colloid, and is characterized in that the polymerization is controlled such that the gelling effect occurs at least at times, which is achieved by the monomer addition (dosing time) taking place for 40 minutes, particularly preferably for 30 minutes.

Abstract: The present invention relates to a norbornene-based crosslinked polymer containing at least one member selected from the group consisting of dicyclopentadiene-based monomer units, tetracyclododecene-based monomer units, and tricyclopentadiene-based monomer units in an amount of 50% by mass or more, wherein the norbornene-based crosslinked polymer has a glass transition temperature of 240° C. or higher. Further, the present invention relates to a method for producing a norbornene-based crosslinked polymer as defined above, including step (1): heating a blend containing at least one member of the above monomer components, and a metathesis polymerization catalyst to a temperature lower than a deactivation temperature of the metathesis polymerization catalyst to carry out a primary curing; and step (2): heating a cured product obtained in the step (1) to a temperature equal to or higher than the deactivation temperature of the above metathesis polymerization catalyst to carry out a secondary curing.

Abstract: The present disclosure relates to the homopolymerization of terpenoids containing an alcohol functional group by free radical polymerization.

Abstract: A low viscosity polymer having a linear or branched backbone derived from farnesene monomers and at least one terminal-end functionalized with a hydroxyl group. This polymer may be further hydrogenated to reduce unsaturation and acrylated, such that it may be incorporated into a LOCA composition. The LOCA composition may be used in a laminated screen assembly, such as a touch screen, for electronic devices by adhering the LOCA composition between an optically transparent layer, such as a cover glass, and a display. The cured LOCA composition has a refractive index similar to the optically transparent layer. A method of making the low viscosity polymer for the LOCA composition includes anionically polymerizing farnesene monomers, quenching a living end of the polymer to provide the hydroxyl-terminated polymer; hydrogenating the hydroxyl-terminated polymer; and reacting the at least partially saturated hydroxyl-terminated polymer with at least one reagent to provide an acrylate terminated hydrogenated polymer.

Abstract: The present invention is directed to a heterophasic propylene copolymer (HECO), a polyolefin composition (PO) comprising the heterophasic propylene copolymer (HECO), an automotive article comprising the heterophasic propylene copolymer (HECO) and/or the polyolefin composition (PO) and a process for the preparation of the polyolefin composition (PO) as well as the use of the heterophasic propylene copolymer (HECO) for improving the mechanical properties of a polyolefin composition (PO).

Abstract: The present disclosure generally relates to ethylene alpha-olefin copolymers and methods of making ethylene alpha-olefin copolymers. The ethylene alpha-olefin copolymers may have a density of about 0.915 g/mL to about 0.918 g/mL, a rheological polydispersity index greater than 0.8, a melt index of about 0.4 dg/10 min to about 2.0 dg/10 min, and/or a CEF T50 of 84° C. or less. The ethylene alpha-olefin copolymers may be made by combining an ethylene monomer and one or more alpha-olefin monomers in the presence of a catalyst, such as a Ziegler-Natta catalyst.